LFCR

$4.70-$0.03 (-0.63%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$180.6M

38M shares

52-week range

$3.63 – $8.98

20% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-4.51

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$75M	-41.2%	$-0.48	$-0.50–$-0.46	—	2
2027	$122M	+62.4%	$-0.98	$-1.01–$-0.94	—	2
2028	$130M	+6.6%	$-0.89	$-0.91–$-0.87	—	1
2029	$150M	+15.6%	$-1.18	$-1.21–$-1.15	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-05	$-0.19	$-0.43	-126.3%
2026-03-16	$-0.14	$-0.16	-14.3%
2025-11-06	$-0.30	$-0.29	+3.3%
2025-08-07	$-0.09	$-0.10	-11.1%
2025-04-03	$-0.14	$-0.47	-235.7%
2025-01-02	$-0.27	$-0.25	+7.4%
2024-10-04	$-0.46	$-0.49	-6.5%
2024-08-26	$-0.12

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
LFCRLifecore Biomedical, Inc.	$4.59	-2.96%	$172M	—
ACBAurora Cannabis Inc.	$3.71	-2.24%	$229M	—
ACHVAchieve Life Sciences, Inc.	$7.27	+0.28%	$746M	—
BIOABioAge Labs Inc.	$10.26	-1.63%	$386M	—
CGCCanopy Growth Corporation	$1.00	-0.99%

Lifecore Biomedical, Inc. Common Stock

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

www.lifecore.com

Employees: 382
IPO / List date: Feb 15, 1996
HQ: CHASKA, MN

Held by traders on TradeandTell

No one on the platform currently holds LFCR.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2024-06-30	11,000	$56.4K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded LFCR yet.

$LFCR chatter on StockTwits

11th.com@11thestate1h
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $LFCR how you can actually recover something: https://11th.com/cases/lifecore-investor-settlement
View on StockTwits ↗
MarketBeat Earnings@EarningsInsiderAug 5
https://www.marketbeat.com/earnings/reports/2026-8-5-lifecore-biomedical-inc-stock/ $LFCR Lifecore Biomedical Earnings Transcript
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsAug 5
$LFCR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.19 up 24.00% YoY • Reported revenue of $34.17M up 4.92% YoY
View on StockTwits ↗
11th.com@11thestateJul 30
Everything You Need to Know About the $3.75M Lifecore Biomedical ($LFCR) Settlement Payout Q: What happened? A: Lifecore Biomedical was accused of misleading investors about its internal controls, inventory management, and financial reporting. The company later disclosed accounting issues, delayed SEC filings, and material weaknesses in its controls, sending the stock lower. Q: Am I actually eligible? A: If you bought $LFCR shares between 2020 and 2024, you're likely eligible. You don't need to still own the stock to file a claim, past losses count Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. The exact timing depends on the court and settlement administration. Q: I missed the deadline. Is it too late? A: You may still be able to file a late claim, but acceptance depends on final approval by the court. Check if you're eligible and file a claim: https://11th.com/cases/lifecore-investor-settlement
View on StockTwits ↗
Ravion | Market News Filter@Ravion_News_FilterJul 28
$LFCR 🤝 Lifecore Biomedical signs three new customer agreements including a technology transfer agreement for a regenerative medicine late-stage program and two early-stage programs for a global medical technology company, expected to contribute to 2028 revenue.
View on StockTwits ↗
11th.com@11thestateJul 16
The $3.75M Lifecore Biomedical investor settlement is now accepting late claims. Investors who purchased $LFCR shares between 2020 and 2024 may still be eligible to participate, late claims are currently being accepted: https://11th.com/cases/lifecore-investor-settlement
View on StockTwits ↗
11th.com@11thestateJul 1
Reminder: If you bought $LFCR, there are 6 days left to file a claim in the $3.75M investor settlement before the July 7, 2026 deadline. If you purchased $LFCR shares between 2020 and 2024, you may be eligible. The settlement claims Lifecore Biomedical misled investors about its accounting, inventory management, and internal controls. After those issues were disclosed, the stock declined. You can check your eligibility and submit a claim before the deadline: https://11th.com/cases/lifecore-investor-settlement
View on StockTwits ↗
11th.com@11thestateJun 18
Imagine buying $LFCR at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $LFCR investors out there, we’ve got some important news for you: A $3.75 million recovery fund is officially open to shareholders who bought between 2020 - 2024. The deadline is next months, you can check if you’re eligible and claim your share here: https://11th.com/cases/lifecore-investor-settlement
View on StockTwits ↗
DARKP00L@DARKP00LJun 16
$LFCR 08:27 on Jun. 16 2026 Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5 #tradeideas
View on StockTwits ↗
jorge .miguel@focafoca99Jun 15
$LFCR signed a new agreement to provide tech transfer and commercial manufacturing for a neurological injectable for a global pharma
View on StockTwits ↗
DARKP00L@DARKP00LJun 15
$LFCR 07:18 on Jun. 15 2026 Lifecore Biomedical Announced It Has Signed A New Agreement With A Global Pharmaceutical Company #tradeideas
View on StockTwits ↗
jorge .miguel@focafoca99Jun 5
$LFCR authorized a 2026 Stock Incentive Plan, approved by shareholders at its annual meeting.
View on StockTwits ↗
11th.com@11thestateJun 4
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $LFCR investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/lifecore-investor-settlement
View on StockTwits ↗
Top Stock Alerts@topstockalertsJun 3
$LFCR that little pause may have only added fuel 🔥
View on StockTwits ↗
DARKP00L@DARKP00LJun 2
$LFCR 07:07 on Jun. 02 2026 Lifecore Biomedical Signs Manufacturing Services Agreement To Perform Process Development And Technical Transfer Services In Support Of Anticipated Commercial Manufacturing Upon Regulatory Approval #tradeideas
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.